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Abstract: 
 
Cerebrovascular disease encompasses a range of pathologies affecting different 
components of the cerebral vasculature and brain parenchyma. Large artery 
atherosclerosis, acute cerebral ischaemia, and intracerebral small vessel disease all 
demonstrate metabolic processes that are key to pathogenesis. Although structural 
imaging has been a mainstay of stroke clinical care and research, it has limited ability 
to detect these pathophysiological processes in vivo. Positron emission tomography 
(PET) provides a means to detect and quantify metabolic processes in each facet of 
cerebrovascular disease non-invasively. The use of PET has helped shape the 
understanding of key concepts in cerebrovascular medicine, including the vulnerable 
atherosclerotic plaque, salvageable ischaemic penumbra, neuroinflammation and 
selective neuronal loss after ischaemic insult, and the relationships between chronic 
hypoxia, neuroinflammation, and amyloid deposition in cerebral small vessel disease. 
This review considers how the ability to image these processes at the neurovascular 
interface has contributed to our understanding of cerebrovascular disease and 
facilitated translational research to advance clinical care.  
 
Key Points: 
 
• PET allows non-invasive detection and quantification of inflammation, 
microcalcification, and hypoxia that are associated with plaque rupture in 
carotid atherosclerosis. 
• The temporospatial evolution of acute ischaemia and secondary 
neuroinflammation can be visualised using PET. 
• PET has elucidated the complex interaction between cerebral small vessel 
disease, neuroinflammation, and amyloid deposition, demonstrating different 
patterns within vascular cognitive impairment. 
• Metabolic imaging with PET provides not only improved understanding of 
disease mechanisms but can also provide sensitive endpoints in clinical trials 
and has the potential to improve clinical risk-stratification. 
  
Introduction: 
 
Positron emission tomography (PET) is increasingly used in neuroimaging research 
strategies, both to image the cerebral arteries and the brain parenchyma, and has 
contributed significantly to our understanding of cerebrovascular disease and 
translational research to advance clinical care. Although structural imaging has been a 
mainstay in stroke research and clinical care, such imaging provides only limited 
insight into important physiological processes. Improved understanding of the role of 
intra-plaque inflammation in triggering carotid atheroma rupture and 
thromboembolism means that a purely anatomical approach based solely on the 
degree of luminal stenosis is over-simplistic and risks overlooking the role of 
symptomatic, but non-stenosing, atheroma1,2. Assessment of plaque physiology in 
vivo may facilitate the development of better treatment approaches, risk-stratification 
of plaque to guide clinical management, and improved monitoring of treatment effects 
from therapy in clinical care and research trials3,4. In acute stroke, metabolic imaging 
has shaped the concept of the salvageable penumbra, providing the basis for 
radiological assessments of perfusion to guide acute reperfusion therapy, as well as 
potentially extending the time window for such therapy5. Finally, PET imaging has 
improved our understanding of pathophysiology in small vessel disease – particularly 
the interaction between chronic cerebrovascular disease, amyloid deposition, and 
cognitive impairment – that may guide the development of new treatments for what is 
effectively an untreatable disease currently. 
 
This review considers different facets of cerebrovascular disease – including the 
metabolic pathophysiology of carotid atherosclerosis, metabolic changes in the 
penumbra in the acute period, and the neuroinflammatory changes associated with 
small vessel disease and vascular cognitive impairment – and how PET has elucidated 
these pathologies at the neurovascular interface to facilitate clinical exploitation.   
 
Principles of PET: 
 
PET allows detection of physiological processes by using targeted radioligands. 
Radioligands target physiological processes through a number of mechanisms, 
including cellular uptake (e.g. the glucose analogue 18F-fluorodeoxyglucose, FDG6), 
incorporation into products of metabolism (e.g. incorporation of 18F-sodium fluoride, 
NaF, into microcalcification7), or via targeting cell surface receptors (e.g. binding to 
peripheral benzodiazepine receptors by N-butan-2-yl-1-(2-chlorophenyl)-N-
methylisoquinoline-3-carboxamide, PK111958) (TABLE 1). Once positron-emitting 
radioligands accumulate in a region of interest (ROI), positrons rapidly encounter 
electrons within local tissues, resulting in annihilation reactions. The release of 
gamma photons is subsequently detected and quantified by scintillation detectors and 
co-localised to anatomical regions through co-registration with computed tomography 
(PET/CT) or magnetic resonance imaging (PET/MRI).  
 
PET in Vascular Risk:  
 
Atherosclerosis and the Vulnerable Plaque: 
 
Carotid atherosclerosis is estimated to underlie 20% of ischaemic strokes. 
Atherosclerotic plaque rupture with subsequent thromboembolism is a key event 
triggering ischaemia, and may occur independently of the degree of luminal stenosis9. 
The atherosclerotic plaque, formed by the infiltration of circulating monocytes with 
subsequent maturation to macrophages and development of a necrotic core, is 
contained within a fibrotic cap1. Metabolic processes including inflammation, 
microcalcification (calcium deposition smaller than 50 micrometers detected by ex 
vivo µCT10), and hypoxia, represent a mix of chemical and mechanical triggers that 
increase the risk of fibrous cap rupture, the so-called “vulnerable plaque.”1,11-13  
 
Conventional clinical imaging is limited in its ability to detect these 
pathophysiological processes and subsequently most clinical imaging remains 
structural, using the degree of luminal stenosis to determine management. Magnetic 
resonance imaging (MRI) has facilitated improved detection of morphological 
features associated with plaque vulnerability (necrotic core size, fibrous cap 
thickness, intraplaque haemorrhage)14, though such imaging remains technically 
demanding and has limited ability to detect microcalcification. In contrast, PET 
provides a highly sensitive non-invasive imaging modality to detect 
pathophysiological processes predisposing to plaque rupture. 
 
Quantification of tracer uptake is measured using standardised uptake values (SUV), 
where measured tracer uptake in a ROI is adjusted according to injected dose and 
patient weight. Although used widely in solid organs, this method has shortcomings 
when used in vascular imaging as it fails to consider the effect of tracer pooling 
within the blood15. Tissue-to-background ratios (TBR) corrects for this by dividing 
SUV within the vessel wall by the SUV in a mid-luminal venous region16. The most 
accurate method remains the subject of debate17. 
 
Different PET tracers have been used to image different processes in atherogenesis: 
macrophage-mediated inflammation (FDG and DOTATATE), microcalcification 
(NaF), and hypoxia (18F-fluoromisonidazole, FMISO). 
 
Plaque inflammation: 
 
Fluorodeoxyglucose: 
 
FDG was the first radiotracer employed in atherosclerosis imaging after incidental 
uptake in carotid arteries was noted in individuals undergoing cancer staging PET18. 
Early clinical studies demonstrated the capacity of FDG-PET to identify culprit 
carotid atheroma in vivo19 (FIG. 1), with subsequent histological studies showing 
FDG uptake correlated strongly with CD68+ macrophage burden in plaques16. Higher 
FDG uptake in symptomatic carotid plaques is also associated with recurrent 
ischaemic stroke, independent of the degree of luminal stenosis20,21. A potential 
mechanism for this is ongoing microembolisation, which was observed (using 
transcranial Doppler ultrasound) in plaques with higher FDG uptake, though the study 
was limited to a small number of symptomatic individuals and lacked correlation to 
clinical outcomes22. 
 
Large histological studies have demonstrated high-risk morphological features 
associated with plaque rupture23. FDG uptake is associated with a number of these 
features, and may provide a means of assessment in vivo24,25. Detection of vulnerable 
plaque has also informed our understanding of atherosclerosis previously considered 
subclinical, with examples of non-stenotic but morphologically high-risk atheroma 
demonstrating increased FDG uptake2,26. Introduction of PET/MRI is likely to provide 
further detail about the interaction between metabolic and morphological processes 
through simultaneous image acquisition. 
 
FDG-PET supports the hypothesis of atherosclerosis as a systemic disease. 
Inflammation within one artery is associated with increased inflammation within 
neighbouring arterial regions27. Higher carotid uptake is also observed in the presence 
of with dental inflammation28, raised low-density lipoprotein and total cholesterol 
levels29, diabetes mellitus30, and metabolic syndrome31. Carotid FDG uptake in 
individuals with recent acute coronary syndrome is higher than in chronic stable 
angina, supporting a systemic upregulation of plaque inflammation that may 
contribute to the clinical phenomenon where acute coronary events and ischaemic 
stroke occur within close temporal proximity32. Furthermore, a recent FDG-PET 
study supports a relationship between the brain and systemic atherosclerosis, with 
stress-related amygdala activity found to be associated with increased bone marrow 
activity, vascular inflammation on FDG-PET, and cardiovascular events33.  
 
FDG-PET studies have indicated important interactions involved in plaque 
progression. Increased inflammation in aortic atheroma is independently associated 
with increased risk of developing macrocalcification34, and the presence of 
macrocalcification within carotid arteries appears to propagate inflammation35. 
 
As well as identifying plaque vulnerability, FDG-PET has furthered understanding of 
therapeutic mechanisms36. An observed reduction in FDG uptake in an asymptomatic 
cohort, independent of the change in low-density lipoprotein, supports the pleiotropic 
effects of statins37. This reduction occurs within weeks of starting a statin, with 
apparent dose-responsive effects38.  
 
FDG-PET is not without its weaknesses. The high sensitivity may be compromised by 
a reduced specificity when uptake in neighbouring metabolically active tissues (e.g. 
lymph nodes, vocal cords) spills-over into adjacent vascular ROIs, resulting in 
artefacts. As FDG is taken up in competition with circulating glucose, it is necessary 
to fast prior to PET/CT, and high circulating glucose will interfere with FDG uptake. 
Finally, renal impairment may lead to prolonged circulating radiotracer that will result 
in artificially low TBR readings39. Adoption of common FDG-PET methodological 
standards and development of more specific radiotracers for inflammation will likely 
minimise these effects and reduce inter-study variability15,40. 
 
Alternative and emerging radiotracers: 
 
11C-N-methyl-N-[1-methylpropyl]-1-[2-chlorophenyl]-isoquinoline-3-carboxamide 
(PK11195) targets translocator protein 18-kDa (TSPO), formerly known as the 
peripheral benzodiazepine receptor (PBR), which is expressed on macrophages. 
PK11195 uptake co-localises with macrophages on histology41,42, and is raised in 
symptomatic carotid atheroma43. However, animal studies found no significant 
difference in PK11195 uptake between atheroma and healthy vessel wall44. This is 
likely due to ubiquitous expression of TSPO, and consequently PK11195’s use for 
atheroma imaging has been limited. However, caution must be exercised when 
applying tracer pharmacokinetics in animal models to humans, due to potentially 
different receptor expression. Second-generation TSPO radioligands have been 
developed with greater specificity and favourable signal-to-noise ratios, though their 
accuracy has been limited by variable receptor binding in humans that is discussed 
further below. 
 
A promising new radiotracer is 68Ga-DOTATATE ([1,4,7,10-tetraazacyclododecane-
N,N′,N″,N″′-tetraacetic acid]-d-Phe1,Tyr3-octreotate) (FIG. 2). Somatostatin receptor 
subtype-2 (SST2) is upregulated on the cell surface of macrophages, to which 
DOTATATE demonstrates high specific binding activity. DOTATATE uptake 
differentiated between symptomatic and asymptomatic carotid plaques in pilot work, 
and correlated strongly with histological macrophage burden and Framingham risk 
scores45. DOTATATE’s superior specificity relative to FDG results in improved 
signal-to-noise ratio, particularly in the coronary arteries. Tracer production does not 
require a cyclotron meaning imaging is much cheaper than using FDG and does not 
require pre-scan fasting.  
 
Microcalcification: 
 
In addition to inflammation triggering plaque rupture via metalloproteinase-mediated 
mechanisms, mechanical destabilisation also plays a role. Microcalcification is 
mediated by osteoblast-like cells derived from vascular smooth muscle cells, a 
process driven by inflammatory cytokines while microcalcification may in turn 
provoke further inflammation46. Microcalcification within the fibrous cap increases 
plaque stress and predisposes to rupture47,48. 
 
CT and MRI are unable to detect microcalcification as it falls below its spatial 
resolution. In contrast, 18F-NaF accumulates at sites of microcalcification, where 
18fluorine is exchanged for the hydroxyl group in hydroxyapatite49. Histological 
validation in carotid endarterectomy samples indicated fluoride co-localised to 
pathological mineralisation7. 
 
Incidental NaF arterial uptake on cancer staging PET was detected in regions with and 
without visible macrocalcification. This, alongside the absence of NaF uptake in some 
areas of macrocalcification, supports NaF binding to sites of active mineralisation 
rather than simply reflecting accumulation in macrocalcification50.  
 
Increased NaF uptake is seen in recently ruptured atheroma and unruptured plaques 
with high-risk features in vivo, indicating tracer uptake reflects increased 
microcalcification and not simply increased binding area following plaque rupture51. 
Similar results have been seen in individuals with stable angina, with a history of 
cardiovascular events, and higher Framingham risk scores52. Recent studies of carotid 
atheroma in transient ischaemic attacks and minor strokes have found increased NaF 
uptake in culprit atheroma53,54. Interestingly, Vesey et al. reported that although NaF 
uptake was higher in culprit versus asymptomatic atheroma, FDG did not differ 
significantly. Similar findings were reported in a smaller dual tracer study of 
symptomatic carotid atheroma55. This contrast to the earlier FDG-PET/CT studies 
supports the concept that the different tracers are targeting two distinct but related 
processes.  
 
NaF uptake correlates with a range of vascular risk factors; age, hypertension, 
hypercholesterolaemia, smoking, diabetes, and a history of prior cardiovascular 
events56. It is also associated with histological characteristics of a vulnerable plaque, 
namely cell death, presence of necrotic core, and macrophage infiltration51.  
 
A dual tracer study in asymptomatic individuals undergoing oncology staging 
demonstrated only 6.5% of arterial lesions showing concomitant FDG and NaF 
uptake; supporting inflammation and microcalcification as two related but distinct 
processes in atherosclerosis57. The presence of macrocalcification appears to alter this 
relationship between inflammation (FDG) and microcalcification (NaF). In a cohort 
of individuals with myeloma, FDG and NaF uptake did not correlate in non-calcified 
lesions, while lower but concordant uptake was noted in mildly calcified lesions 
(r=0.7) and severely calcified lesions (r=0.4)58. These PET studies suggest a temporal 
evolution of atherogenesis with distinct phases and interplay between inflammation, 
microcalcification, and macrocalcification. 
 
Hypoxia: 
 
18F-fluoromisonidazole (FMISO) is a 2-nitroimidazole that undergoes selective 
bioreduction and accumulates within hypoxic cells59. Hypoxia occurs due to 
increasing oxygen demand from foam cells exacerbated by increasing necrotic core 
size, plaque thickness, and distance from the luminal wall60. Higher FMISO uptake 
has been observed in symptomatic than asymptomatic atheroma and correlated with 
FDG uptake, consistent with hypoxia as either a contributing factor to inflammation 
or playing a direct role in FDG uptake61. 
 
Implications: 
 
The ability to define absolute uptake thresholds for stability is currently limited by the 
typically small size of studies and heterogeneous methodologies. van der Valk et al. 
propose a FDG maximum TBR of 1.84 as the upper limit of physiological uptake in 
the carotid, corresponding to the 90th centile of controls62. However, it is important to 
note that in this study the average BMI was 25, which may increase tracer uptake as 
described above. Marnane et al. found a one unit increase in symptomatic artery FDG 
mean SUV resulted in an adjusted (for age and degree of stenosis) hazard ratio of 
recurrent stroke at 90 days of 6.1 (95% CI 1.3-28.8, p=0.02), with a mean SUV 
threshold of 1.85 providing an optimal balance of sensitivity (61.5%) and specificity 
(78.7%) to discriminate between individuals at low and high risk of recurrence20. For 
DOTATATE, a maximum TBR of greater than 2.66 had 87.5% sensitivity and 78.4% 
specificity to detect culprit coronary segments45. For PET to be utilised clinically for 
risk stratification, risk thresholds need to be established for tracer uptake and future 
work should look towards harmonising study protocols to facilitate meta-analysis. 
 
Atheroma PET imaging is highly reproducible with high inter-reporter agreement 
across radiotracers52,63. The high sensitivity means subtle differences in tracer uptake 
are readily detectable and require fewer participants to studies to reach sufficient 
power. Rather than using conventional clinical endpoints, such as recurrent events, 
PET can be used to measure metabolic endpoints in drug trials. The dal-PLAQUE 
phase 2b study used FDG-PET endpoints to test the effects of dalcetrapib, a 
cholesteryl ester transfer protein that raises high-density lipoprotein. Although the 
primary outcome was negative, the study demonstrated the use of metabolic endpoints 
in atherosclerosis trials is feasible4,64. Such an approach may be adopted to understand 
the underpinning mechanisms and establish proof of principle responses to 
intervention, prior to larger studies assessing clinical response.  
 
PET in Acute Ischaemic Stroke:  
 
PET has also provided valuable mechanistic insights in acute infarction, establishing 
the concept of the “salvageable penumbra.” During acute cerebral ischaemia, the 
penumbra represents a region of neuronal dysfunction that may be reversed if cerebral 
perfusion is restored (in contrast to the infarct core where neuronal dysfunction is 
irreversible)65,66. This phenomenon provides the target for acute reperfusion therapy 
in acute ischaemic stroke, as well as underpinning the use of CT-perfusion and MRI 
to identify penumbra to guide this therapy.  
 
Ischaemic injury to the brain provokes a reactive gliosis involving activation of 
astrocytes and microglia, the resident macrophages of the central nervous system. 
Although neuroinflammation is generally seen as contributing to pathophysiology in 
most neurodegenerative conditions, it is believed to play a complex dual role 
following ischaemia. The post-infarct microglial response involves two arms: pro-
inflammatory M1 and anti-inflammatory M2 microglial subtypes, with an early 
polarisation from M2 to M1 subtypes in peri-infarct regions67. M1 microglia exert 
neurotoxic effects through production of reactive oxygen species and pro-
inflammatory proteins, which may themselves perform a dual role. Matrix 
metalloproteinase-9 (MMP-9) exacerbates ischaemic damage by promoting blood-
brain barrier disruption and neuronal death in the early stages post-infarct, but may 
promote brain regeneration and neurovascular remodeling in latter phases68,69. The 
M2 microglial subtype is predominantly protective, with associated neuronal 
survival70. Imaging using PET has helped elucidate the mechanisms underlying the 
neuroinflammatory response to ischaemia and how this response may affect the brain 
beyond the site of infarct. 
 
Penumbra: 
 
15O-PET: 
 
Early 15O-PET measuring tissue perfusion (cerebral blood flow, CBF) and cerebral 
oxygen consumption (CMRO2) identified three distinct groups within a cohort of 
ischaemic stroke patients: extensive areas of greatly reduced CBF and CMRO2, 
extensive moderate CBF reduction but only focal areas of marked CMRO2 reduction, 
and increased CBF with only focal areas showing reduced CMRO2 (FIG. 3). 
Although small studies, these patterns showed proof of principle and matched clinical 
outcomes, with poor, variable, and good outcomes respectively, independent of initial 
neurological status71,72. Acute 15O-PET has found salvageable penumbra of 10-52% of 
the infarct volume up to 17 hours post-infarct73. The presence of penumbra beyond 
conventional clinical thrombolysis windows has led some to call for prospective 
studies assessing the selection for thrombolysis on a case-by-case physiological basis 
(most likely assessed by CT-perfusion; a CT-based dynamic sequential scanning 
technique of the movement of contrast through the vasculature that can be used to 
visualise CBF and cerebral blood volume, the mismatch of which represents the 
penumbra as described above) rather than absolute time cut-offs74,75.  
 
Co-registered 15O-PET and diffusion-weighted imaging (DWI), an MRI sequence 
imaging the diffusion of water molecules with impaired movement resulting in 
generation of increased contrast, implies the DWI lesion includes not only an infarct 
core but also penumbra76. This was supported by further work mapping CBF, 
CMRO2, and oxygen ejection fraction (OEF) onto DWI lesions, which showed a 
heterogeneous pattern of oxygen metabolism within the DWI lesion, as well as 
variation between individuals, and supported the patterns of oxygen metabolism seen 
in the earlier 15O-PET work71,77, indicating that some of DWI lesion may be reversible 
and represent salvageable tissue. Furthermore, “misery perfusion” – regions 
exhibiting low CBF, high OEF, but only moderately reduced CMRO2 – was the 
predominant pattern in the DWI lesion and was also seen outside of the DWI ROI, 
suggesting that there is regional variation determining different perfusion 
thresholds77,78. The use of voxel-based mapping in 15O-PET has allowed thresholds 
for irreversible tissue damage to be estimated: 8.43 ml/100 ml/min for CBF and 0.87 
ml/100 ml/min for CMRO2. Infarcts with higher proportions of voxels below these 
thresholds were associated with larger final infarct volumes and poorer neurological 
outcomes at two months79. The reversibility of DWI lesions, and the salvageable 
tissue it may contain, has important implications for both research methodology 
(which may use DWI volume as endpoints) and clinical practice. 
 
Fluoromisonidazole: 
 
Penumbral mapping has advanced with the introduction of newer PET radiotracers. 
FMISO, accumulating within hypoxic but viable cells, was seen in the peripheries of 
the infarct in 9 of 13 of individuals scanned within 48-hours of infarction but none of 
those scanned at 6-11 days80. Studies using MRI data to strictly define the infarct core 
found FMISO uptake in both the penumbra and core81. FMISO studies have 
demonstrated temporospatial evolution of infarction, with tracer uptake moving from 
the centre to the periphery with increasing time post-infarct82,83. This suggests that 
there is a region of the core that, while unsalvageable and destined to infarct, still 
demonstrates sufficient activity for FMISO uptake. Conversely, FMISO uptake is also 
seen in tissue beyond the symptomatic tissue on co-registered MRI, suggesting 
oligaemic tissue also experiences hypoxia81,84. 
 
FMISO uptake in the acute stage may also be able to predict outcomes, with 80% of 
those with uptake showing an increase in infarct volume compared to no infarct 
growth in those without FMISO uptake85. This is unsurprising given the nature of the 
tissue represented by FMISO uptake, but given the limited ability of MRI to 
differentiate between penumbra and benign oligaemia, this method for quantifying 
vulnerable tissue may have important implications for prognostication. A higher 
proportion of surviving tissue measured by FMISO-PET at 12 hours and between 12-
48 hours post-stroke was associated with better neurological recovery at 3 months86. 
Supporting the findings of 15O-PET, FMISO uptake has also been seen up to 131 
hours after the stroke85. These findings suggest potentially salvageable tissue beyond 
current clinical intervention windows. 
 
Flumazenil: 
 
Impaired functional recovery despite successful reperfusion of penumbra is an 
important clinical issue. 11C-flumazenil (FMZ) offers insights into this phenomenon 
by allowing in vivo imaging of selective neuronal loss (SNL) following ischaemic 
stroke. SNL differs from “pannecrosis” – the widespread necrosis of cells including 
glial cells, neurons, and white matter – in that there is selective death of neurons but 
other cells and the extracellular matrix are preserved87. This selective loss of neurons 
is associated with poorer functional recovery as these activated neurons, found 
predominantly in the peri-infarct cortical areas, determine neuroplasticity after 
stroke88. 
 
FMZ is an antagonist to the benzodiazepine binding site of gamma aminobutyric acid-
type A (GABA-A) receptors, mainly found on neurons. Consequently, SNL results in 
decreased FMZ uptake. FMZ-PET shows potential in differentiating unsalvageable 
tissue from viable penumbra, with the region of decreased FMZ uptake corresponding 
with final infarct volume89. The ability to differentiate between viable and non-viable 
tissue has implications for reperfusion therapy. In 11 patients undergoing 
thrombolysis with decreased CBF, only the 4 individuals with decreased FMZ uptake 
showed evolution to an infarct90. 
 
FMZ-PET has suggested significant SNL in salvaged penumbra, with the reduction in 
FMZ binding proportional to acute-stage hypoperfusion and resulting in reduced 
neuronal activation on MRI91,92. Such findings have clear ramifications for the 
functional recovery in such salvaged penumbra, as well as a potential mechanism to 
explain mismatch of functional deficit and radiological findings in the sub-acute to 
chronic setting.  
 Similar findings associated with carotid stenosis have been seen with decreased FMZ 
binding borderzone territories with reduced CBF but without evidence of infarction, 
suggesting that haemodynamic compromise from large artery disease may be 
associated with SNL93.  
 
FMZ-PET has informed our understanding of oedema formation after middle cerebral 
artery infarction. The use of infarct volume as the conventional predictor for 
malignant oedema has a low positive predictive value. In contrast, FMZ-PET within 
24-hours of infarct found that volume of severe ischaemia, rather than total perfusion 
deficit, predicted development of malignant oedema with a high positive predictive 
value94.  
 
Neuroinflammation: 
 
PK11195: 
 
Imaging neuroinflammation in vivo is possible through the use of PK11195 targeting 
TSPO expressed on microglia (and upregulated upon their activation) but not 
astrocytes following ischaemic damage95. The temporal pattern of microglial activity 
in humans post-infarct with PK11195-PET shows minimal binding within 72-hours, 
increasing within a week before falling by 25-30 days96. The spatial distribution of 
tracer uptake mirrored that described in hypoxia, with uptake initially seen in the core 
at 7-14 days before the peri-infarct zone showed a higher degree of uptake in the sub-
acute phase. Importantly, there was also increased tracer uptake in the contralateral 
hemisphere at latter time points, suggesting that neuroinflammation extends beyond 
the infarct96,97 (FIG. 4). Similar temporal patterns were seen by Gerhard et al., though 
spatial evolution of PK11195 uptake showed movement from the peri-ischaemic 
region to increasing overlap with the MRI-defined infarct region98.  This study, along 
with others, suggests longterm microglial activation remote from the infarct up to 150 
days post-infarct98,99. 
 
It is important to note that differences in spatial patterns may be due to a combination 
of small samples and slightly different time intervals, potentially catching different 
stages of systemic infiltration. More recent animal studies demonstrated a lack of 
PK11195 in the infarct core, instead localising to normoperfused peri-infarct regions 
and co-localising with increased FDG uptake suggesting increased energy demand in 
these regions100. However, caution should again be exercised when comparing 
binding behavior between species. 
 
Remote microglial activation likely indicates Wallerian degeneration along 
anatomically-connected neural networks101,102. Co-registering PK11195 with diffusion 
tensor imaging (DTI), which images the direction of water diffusion in order to 
identify neural tracts, after subcortical infarction showed uptake occurred only in an 
antegrade direction and only if the pyramidal tracts were affected, suggesting the 
spread of activated microglia is specific to affected tracts rather than a non-specific 
disseminated response103,104. The extent of remote microglial activation appears 
independent of infarct size or clinical severity. One clinical study has shown differing 
clinical patterns depending upon the location of activated microglial activity; initial 
PK11195 uptake in the tracts was associated with improved clinical outcomes while 
persistent tracer uptake in the infarct was associated with poorer clinical outcomes104.  
 
Second generation TSPO radioligands: 
 
Quantification of these temporospatial patterns of PK11195 uptake is challenging due 
to non-specific binding, resulting in sub-optimal signal-to-noise ratios, and difficulty 
in defining a reference region for comparison, hence study results should be 
interpreted with this caveat. Newer second-generation TSPO radioligands have 
increased specificity (resulting in improved signal-to-noise) and advantageous 
pharmacokinetics. However, an emergent physiological factor has limited their wider 
adoption. 11C-PBR28 was shown to have improved specificity by a dual PK11195 and 
PBR28 rat study105, but subsequent work comparing receptor binding between animal 
models and humans found receptor binding to be markedly lower in humans 
compared to monkeys, and that there was variation in the human binding with some 
showing no specific binding106. Subsequent studies have revealed polymorphism in 
the gene Ala147Th that results in high-affinity and low-affinity binders, with 
heterozygous individuals displaying intermediate affinity binding107,108. In contrast, 
PK11195 does not appear to have variable affinity as it binds to a different site on the 
TSPO8. These findings show it is important to exercise caution when comparing 
tracer pharmacokinetics between different animal species and humans, as well as 
human subject comparisons. 
 
The short half-life of 11C-labeled radiotracers has important implications for research 
and clinical use. PK11195’s half-life of 20.38 minutes means that an on-site cyclotron 
is essential109. In contrast, the 110-minute half-life of 18F-labeled radiotracers makes 
imaging possible without a cyclotron onsite. One example is 18F-N,N-diethyl-2-(2-(4-
(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-α]pyrimidin-3-yl)acetamide 
(DPA-714). DPA-714 rapidly accumulates within the infarct, with detectable uptake 
reaching a peak 5 minutes after tracer injection, and supports earlier findings that the 
extent of microglial activation does not correlate with the size of the infarct110. No 
direct comparison between PK11195 and DPA-714 has been performed in humans, 
though direct comparison in rat models shows DPA-714 to have a superior signal-to-
noise ratio111,112. 11C-vinpocetine demonstrated higher uptake in infarct core, peri-
infarct region, and contralateral hemisphere that PK11195 in human subjects post-
infarct, though the difference did not reach statistical significance113,114. Newer TSPO 
ligands, such as 18F-GE-180, have shown superiority to PK11195 in animal models 
but their application within humans is yet to be seen. Furthermore, it remains to be 
seen if DPA-714, vinpocetine, and GE-180 are also affected by variable TSPO 
affinity. 
 
Implications: 
 
Although PK11195 and second-generation TSPO ligands provide means of detecting 
activated microglia, they are unable to differentiate between M1 and M2 subtypes. 
Understanding the pattern in vivo of these different subtypes, and how they relate to 
the imaging results discussed above, would provide important mechanistic 
information to further understand their different roles in post-stroke 
neuroinflammation.  
 
The use of PET/MRI will likely enable greater accuracy through simultaneous 
acquisition of DTI and tracer co-localising compared to previous studies where these 
scans were performed on different machines at different time points. 
 PET in Chronic Small Vessel Disease: 
 
Chronic cerebral small vessel disease (SVD) – disease in the perforating cerebral 
arteries and arterioles – is a major cause of vascular cognitive impairment (VCI). VCI 
may occur as a result of several different vascular pathologies characteristic of SVD: 
microinfarcts from arteriolar occlusion, lacunar infarction, or diffuse white matter 
injury through incomplete infarction115. Furthermore, SVD may interact with 
neuroinflammation, microhaemorrhages, and amyloid deposition in the development 
of cognitive impairment. Although structural imaging can confirm the presence of 
white matter hyperintensities (WMHs), not all WMHs will be symptomatic. PET has 
helped the understanding of their natural history, and provided potential imaging 
surrogate markers of disease in research and clinical applications. 
 
Formation and Implications of WMH: 
 
Cognitive decline in VCI is attributed to damage of the white matter, particularly 
subcortical. The degree of cognitive impairment has only a limited association with 
the degree of WMHs seen on MRI, but has a stronger correlation with hypoperfusion 
and hypometabolism116. This hypometabolism can be visualised with FDG-PET, 
where focal reductions in signal tend to be asymmetric, which can be differentiated 
from the global reduction seen in Alzheimer’s dementia117.  
 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) provides an effective model of SVD. In these 
individuals, the regional cerebral metabolic rate of glucose measured by FDG-PET is 
significantly reduced in cortical and particularly subcortical structures compared to 
controls118. Both a reduction in CBF and neuronal loss may contribute to these 
findings. 15O-PET-measured CBF reduces in a dose-dependent manner for individuals 
heterozygous and homozygous for a CADASIL-causing R133C mutation compared to 
controls119.   
 
Individuals with essential hypertension and WMHs who experienced cognitive 
decline over the three-year follow-up had significantly lower CBF on 15O-PET at 
baseline compared to those without cognitive decline, likely a consequence of small 
vessel remodeling120. This reduction in CBF and intermittent hypoxia is in turn likely 
to trigger a neuroinflammatory response. 
 
Chronic Neuronal Pathology and Neuroinflammation: 
 
The activation of microglia, particularly their role in MMP-mediated blood-brain 
barrier disruption, is important in chronic cerebrovascular disease. The microglial 
response following infarction is described above, but microglial activation also 
accompanies chronic SVD in human post-mortem studies121.  
 
Polarisation of microglia from protective M2 to neurotoxic M1 subtypes represents a 
potential therapeutic opportunity in SVD. Minocycline, a tetracycline antibiotic with 
anti-inflammatory action, selectively inhibits the polarisation of pro-inflammatory M1 
microglia122. In animal models of focal infarction, minocycline reduced microglial 
activation, improved neurogenesis, reduced infarct volumes, and improved functional 
outcomes123,124. In animal models minocycline significantly reduced white matter 
damage, most likely through inhibition of hypoxia-inducible factor-1α and MMP-9 
and consequent reduction in blood-brain barrier disruption125,126. PK11195 studies are 
currently underway assessing whether similar results are seen in humans.  
 
Links between SVD and Alzheimer pathology: 
 
PET has furthered understanding of interactions between SVD and Alzheimer’s 
pathology observed in epidemiological studies and post-mortem studies127. 
Accumulation of amyloid precursor protein (APP) has been detected in areas of 
chronic hypoperfusion and acute infarction128, and amyloid beta (Aβ) protein 
localised to areas of SVD in human post-mortem specimens129. Overexpression of 
APP is associated with a greater reduction in cerebral blood flow and larger volumes 
of infarcts in transgenic mice130. This mechanism has proven harder to demonstrate in 
humans, though PET using N-methyl-[11C]2-(4’-methylaminophenyl)-6-
hydroxybenzothiazole (PiB) has suggested processes not observable in structural 
imaging. PiB is an analogue of thioflavin-T that binds with high affinity to aggregated 
amyloid131. Individuals with recent infarcts were found to have elevated PiB uptake in 
the peri-infarct region in the sub-acute phase132 (FIG. 5). However, this study, like 
earlier animal studies, is limited in its ability to conclude whether Aβ contributed to 
infarct development or whether it is a consequence of ischaemia. 
 
FDG uptake is lower in WMHs in individuals with abnormally high cerebrospinal 
fluid Aβ protein concentrations, implying an association between amyloid 
dysmetabolism and WMHs133. Longitudinal studies using PiB and MRI suggest that 
amyloid burden can interact with SVD burden in individuals with VCI, particularly in 
semantic word fluency and global dementia rating134. The burden of WMH is 
associated with increased progression of amyloid burden assessed by PiB, suggesting 
SVD results in impaired amyloid clearance135.  
 
PiB uptake has been found to be associated with a four-fold increase in the risk of 
developing incident dementia within six months after stroke/TIA136. PET may also be 
able to discriminate between pathology in early- and late-onset subcortical VCI, 
where early-onset disease was associated with a higher number of lacunes but late-
onset disease showed higher PiB uptake, despite no significant difference in WMH 
volumes137. As well as suggesting different pathological bases, this study also found 
differences in structural changes, with a decrease in mean cortical thickness and 
hippocampal volume associated with PiB uptake. Amyloid burden measured by PiB 
appears to affect cortical atrophy and cognitive impairment without mediation by the 
white matter network, in contrast to SVD that did result in network disruption138. 
Similarly, dual PiB and MRI studies have shown periventricular WMH volume, but 
not PiB uptake, was associated with gait disturbance in SVD139. 
 
The above shows potential utility of PiB-PET to delineate pure models of subcortical 
vascular dementia from Alzheimer pathology in mixed dementia. In a large PET 
study, two thirds of those diagnosed clinically with vascular dementia did not show 
PiB uptake, and this cohort performed better on memory testing but worse on frontal 
function tests than individuals with PiB-positive Alzheimer’s disease140. 
 
Cerebral amyloid angiopathy: 
 
PiB also has a potential role in the assessment of cerebral amyloid angiopathy (CAA), 
a chronic cerebral vascular disease characterised by infiltration of Aβ protein with 
associated microhaemorrhages, macrohaemorrhages, and microinfarcts, 
predominantly in a lobar distribution. PiB uptake appears increased in individuals 
with probable CAA in this cortical pattern141. CAA was observed to contribute to the 
development of WMH in SVD, likely through angiopathy-induced hypoxia, with 
global PiB uptake and WMH being strongly correlated in individuals with CAA. 
However, there was no similar relationship for PiB uptake in Alzheimer’s disease, 
suggesting that the finding in CAA relates directly to the angiopathy142. 
 
Limitations: 
 
Serial longitudinal imaging using PET/CT is limited by radiation exposure: a 250 
MBq FDG-PET/CT of the carotids involves an additional radiation exposure of 5.5 
mSv. Consequently, its use clinically in primary prevention for risk-stratifying 
atheroma identified through screening is limited by the uncertainty of when to scan.  
 
As discussed above, although FDG-PET/CT is highly sensitive for inflammation, it 
has a lower specificity owing to tracer uptake in other metabolically active tissue. 
This is compounded by the limited spatial resolution of PET (3mm). Both of these 
considerations result in the potential for a partial volume effect, where there is 
difficulty differentiating tracer activity within an ROI from that of neighbouring 
tissues due to “spill-in” or “spill-out” (where signal from the tissue of interest falls 
outside of the ROI). This may be reduced by designing protocols that minimise 
physiological uptake in surrounding structures (keeping patients silent and nil by 
mouth, ensuring blood sugar control) and reduce movement artefact (appropriate 
head/neck supports). Partial volume error may also be reduced through the use of 
geometric transfer matrices and algorithms, where tracer uptake is matched to a 
voxel-based analysis from a higher resolution imaging modality helps restrict signal 
quantification to a specific region143,144. 
 
The availability, cost, and radiation exposure involved in PET studies involving 
human subjects has typically resulted in studies with small sample sizes. The 
sensitivity of PET means that small physiological changes may be detected, 
facilitating statistically significant differences to be detected using these small 
numbers. However, it can be difficult to draw conclusions about clinically-relevant 
thresholds (e.g. level of plaque rupture) due to the small samples and potential 
selection bias of retrospective studies that limit the ability to perform robust multi-
variable analysis. Differences in methodology, tracer administration, reconstruction of 
images, and tracer uptake measures further limit direct comparisons, with SUV values 
found to vary by a factor greater than three in some carotid FDG-PET/CT studies17. 
Currently, the body of cerebrovascular PET studies should be viewed as indicating 
important physiological mechanisms and general trends in disease patterns, with the 
potential for clinical application if the above considerations can be overcome. 
 
Conclusions and future applications: 
 
Although widespread clinical use of PET remains unlikely for the reasons described 
above, there may be potential clinical applications for assessing treatment responses 
in particularly high-risk arteriopathic individuals. For widespread clinical adoption, 
the use of PET for determining treatment in a randomised control trial would be 
required. However, the strength of PET is its ability to elucidate disease mechanisms, 
identify novel therapeutic targets, and its use as a potentially powerful tool for 
providing outcome measures in therapeutic trials. The dal-PLAQUE study has already 
shown how PET can be used effectively in atheroma drug trials. Similar approaches 
are currently being used in evaluating neuroinflammatory responses to treatment. 
Beyond pharmacological monitoring there is potential to elucidate the mechanisms 
underlying stroke rehabilitation. For example, post-infarct rehabilitation appears to 
reduce the proliferation of microglia around the infarct with improved functional 
recovery in animal models145.  
 
Newer PET ligands continue to be developed with superior specificity or for targeting 
new processes of interest. Epoxide hydrolase (sEH), an enzyme inactivating 
epoxyeicosatrienoic acids that have vasoactive and anti-inflammatory properties, is 
implicated in neuronal damage and has been found to be elevated in individuals with 
VCI146.  N-(3,3-diphenylpropyl)-6-18F-fluoronicotinamide (FNDP) targets sEH with a 
specificity of 80-90% in animal models147. PET tracers to the α7 nicotinic 
acetylcholine receptor (expressed on neurons, astrocytes, microglia, and endothelial 
cells) have shown proof-of-principle applications for use in both intracerebral and 
vascular imaging148,149. Radiotracers specific for apoptosis, such as those targeting 
caspase-3 within the apoptotic pathway, are also in development150.  
 
It is important that the field consider adopting uniform methodologies to allow direct 
comparison of results and to facilitate meta-analysis with larger samples. Despite the 
first vascular FDG-PET studies having been performed 15 years ago, calls for 
harmonisation of methods persist17,19. As the number of radiotracers increases for 
imaging the different facets of cerebrovascular disease, it is vital that similar 
standardisation occur but at a much earlier stage. 
 
PET is a versatile in vivo imaging technique that can provide important mechanistic 
insights across the range of neurovascular pathologies in cerebrovascular disease. The 
improved structural imaging offered by MRI in PET/MRI is likely to provide 
improved anatomical co-registration and simultaneous acquisition of both 
structural/morphological and metabolic imaging. This has the potential to advance our 
understanding of both vascular and intracerebral pathophysiology in cerebrovascular 
disease.  
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Tracer Molecular target Cellular/physiological 
target 
Technical 
considerations 
18F-FDG Cellular uptake Inflammation/metabolism High sensitivity 
but potential for 
sub-optimal 
signal-to-noise 
ratios 
68Ga-
DOTATATE 
Somatostatin 
receptor subtype-
2 (SST2) 
Macrophages High specific 
binding activity 
18F-NaF Hydroxyapatite Microcalcification Potential spill-
over from 
vertebrae or 
mandible 
18F-FMISO Selective 
reduction in 
hypoxia 
Hypoxia Long tracer 
uptake time (120 
– 180 minutes) 
11C-PK11195 TSPO Macrophages/microglia Short half-life, 
sub-optimal 
signal-to-noise 
intracerebrally 
11C-PBR28 TSPO Macrophages/microglia Variable affinity 
binders and short 
half-life 
18F-DPA-714 TSPO Macrophages/microglia Superior signal 
to noise ratio but 
paucity of 
human data 
11C-vinpocetine TSPO Macrophages/microglia Superior signal 
to noise ratio but 
paucity of 
human data and 
short haf-life 
18F-GE-180 TSPO Macrophages/microglia Superior signal 
to noise ratio but 
paucity of 
human data 
11C-FMZ GABA-A 
receptor 
Neurons Short half-life 
11C-PiB Analogue of 
thioflavin T 
Amyloid Short half-life 
Table 1: Radiotracers used in vascular and cerebrovascular PET studies. 
